首页 | 官方网站   微博 | 高级检索  
     

拓扑异构酶Ⅰ抑制剂研究进展
引用本文:刘潇,王汝冰,符伟,李志裕.拓扑异构酶Ⅰ抑制剂研究进展[J].药学进展,2009,33(7):311-320.
作者姓名:刘潇  王汝冰  符伟  李志裕
作者单位:中国药科大学药物化学教研室,江苏,南京210009
摘    要:综述近年来拓扑异构酶Ⅰ抑制剂的研究进展,分类介绍其抗肿瘤活性以及构效关系,并分析讨论其与靶酶结合作用的特点,旨在为设计、合成与筛选新型拓扑异构酶Ⅰ抑制剂候选化合物提供一定参考。DNA拓扑异构酶Ⅰ是抗肿瘤药的重要靶点,随着对酶的构象及其抑制剂的深入研究,多种高效低毒的化合物被相继发现并进入临床研究阶段,为肿瘤患者带来了希望。

关 键 词:拓扑异构酶I抑制剂  抗肿瘤药  喜树碱  吲哚并咔唑  茚并异喹啉酮

Advances in the Researches on Topoisomerase I Inhibitors
LIU Xiao,WANG Ru-bing,FU Wei,LI Zhi-yu.Advances in the Researches on Topoisomerase I Inhibitors[J].Progress in Pharmaceutical Sciences,2009,33(7):311-320.
Authors:LIU Xiao  WANG Ru-bing  FU Wei  LI Zhi-yu
Affiliation:(Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China)
Abstract:The advances in researches on topoisomerase Ⅰ (topo Ⅰ) inhibitors were introduced, and the species, anticancer activities and their structure-activity relationships (SARs) were summarized. We also analyzed the correlativity between the crystal structure of the ternary complex and their SARs, in order to offer reference for designing, synthesizing and screening new topo Ⅰ inhitibor candidates. The topo Ⅰ has become a useful therapeutic target against cancer, and with the incessant discovery into the conformation of topoisomerase and the related inhitibors, many kinds of compounds with high-eflqciency and low toxicity were discovered. Moreover, some compounds have already entered into the clinical research successfully, which has brought hope for cancer patients.
Keywords:topoisomerase Ⅰ inhibitor  anticancer agents  camptothecins  indolocarbazoles  indenoisoquinolones
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号